VYNE Therapeutics Inc.
VYNE
$1.43
-$0.45-23.94%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -12.02M | -12.16M | -9.41M | -6.25M | -6.19M |
| Total Depreciation and Amortization | 4.00K | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 154.00K | 229.00K | 269.00K | 207.00K | 456.00K |
| Change in Net Operating Assets | 2.87M | 3.42M | 656.00K | -1.94M | 595.00K |
| Cash from Operations | -9.00M | -8.51M | -8.48M | -7.98M | -5.14M |
| Capital Expenditure | -117.00K | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 12.86M | -4.82M | 19.02M | -3.57M | -62.35M |
| Cash from Investing | 12.74M | -4.82M | 19.02M | -3.57M | -62.35M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | 82.67M |
| Repurchase of Common Stock | -132.00K | -2.00K | -3.00K | -4.00K | -2.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | 0.00 |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -132.00K | -2.00K | -3.00K | -4.00K | 82.66M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 3.61M | -13.34M | 10.54M | -11.56M | 15.17M |